BriaCell Therapeutics Corp. (NASDAQ:BCTX) Sees Large Increase in Short Interest

BriaCell Therapeutics Corp. (NASDAQ:BCTX) saw a significant growth in short interest in the month of September. As of September 15th, there was short interest totalling 1,650,000 shares, a growth of 549.1% from the August 31st total of 254,200 shares. Based on an average trading volume of 3,560,000 shares, the days-to-cover ratio is presently 0.5 days. Currently, 6.7% of the shares of the stock are sold short.

BriaCell Therapeutics Trading Up 16.6 %

Shares of BCTX traded up $0.10 during mid-day trading on Wednesday, reaching $0.74. The company’s stock had a trading volume of 2,397,943 shares, compared to its average volume of 1,333,047. BriaCell Therapeutics has a 52 week low of $0.46 and a 52 week high of $6.36. The company’s fifty day moving average price is $0.68 and its two-hundred day moving average price is $1.47.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright dropped their target price on shares of BriaCell Therapeutics from $18.00 to $15.00 and set a “buy” rating for the company in a research report on Thursday, September 19th.

Institutional Investors Weigh In On BriaCell Therapeutics

An institutional investor recently raised its position in BriaCell Therapeutics stock. Onyx Bridge Wealth Group LLC increased its position in BriaCell Therapeutics Corp. (NASDAQ:BCTX) by 66.7% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 50,000 shares of the company’s stock after buying an additional 20,000 shares during the quarter. Onyx Bridge Wealth Group LLC owned 0.31% of BriaCell Therapeutics worth $143,000 as of its most recent filing with the Securities & Exchange Commission. 15.42% of the stock is currently owned by institutional investors and hedge funds.

BriaCell Therapeutics Company Profile

BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers.